Home › Persian Gulf Syndrome › NCT06515184
Coenzyme Q10 for Gulf War Illness: A Replication Study
RecruitingPhase 3
Who can join
Ages 50 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Meets both CDC and Kansas deployment and symptom inclusion criteria. * Does not have a disqualifying condition. * Able to travel to a local Quest facility for study blood draws. * Adequate internet access to allow ZoomPro visit participation and remote survey completion. * Health prior to the Gulf War rated as "very good" or "excellent" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms). * Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation. Exclusion Criteria: * Participating in another clinical trial. * Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use. * On Coumadin/ warfarin. * Unable to participate for the required duration of the study.
About the study
The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.
What is being tested
- PharmaNord Bio-Quinone Active CoQ10 Gold 100mg (drug)
- PharmaNord Placebo (drug)
- PharmaNord Bio-Quinone Active CoQ10 Gold 100mg (drug)
Sponsor: University of California, San Diego · Participants: 192 · Started: Sep 13, 2024
Contact the study team
- Janis B Ritchie, BSN · Phone: 858-558-4950
Official record on ClinicalTrials.gov — NCT06515184
Locations in the U.S.
| California | UC San Diego, La Jolla |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.